Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) has filed its Monthly Return for the period ended 30 June 2026, highlighting a sizeable A-share repurchase and confirming continued compliance with Hong Kong’s public-float rules.

TIGERMED bought back 20.96 million A-shares on the Shenzhen Stock Exchange between 10 and 25 June 2026 at prices ranging from RMB 38.74 to RMB 42.65 per share. The total cash consideration reached approximately RMB 824.32 million, implying an average repurchase price of about RMB 39.33 per share.

As a result of these transactions: • Outstanding A-shares (excluding treasury) fell 2.86 % month-on-month to 711.05 million. • Treasury A-shares expanded from 5.88 million to 26.85 million, now representing 3.64 % of the 737.90 million issued A-shares. • Combined with 123.12 million H-shares (unchanged during the month and with no treasury stock), TIGERMED’s total shares in issue, excluding treasury, stand at approximately 834.18 million.

Authorised and registered share capital remained unchanged at 861.03 million shares (par value: RMB 1 each). The company reported no new share issues, options, warrants, convertibles, or other equity instruments during the month.

TIGERMED confirmed that its H-share public float continues to satisfy the Hong Kong Stock Exchange’s minimum 5 % requirement.